For US healthcare professionals
Indicated for reduction in the duration of severe neutropenia in patients with nonmyeloid
malignancies receiving myelosuppressive anticancer drugs associated with a clinically
significant incidence of febrile neutropenia.
Important Safety Information: Splenic rupture, including
fatal cases, can occur following the administration of human granulocyte colony-stimulating
factors (hG-CSFs). Discontinue GRANIX and evaluate for an enlarged spleen or splenic
rupture in patients who report upper abdominal or shoulder pain after receiving
Storage, administration & dosing
Cost & reimbursement
Trusted to take a bite out of G-CSF acquisition
Based on wholesale acquisition cost (WAC) of short-acting G-CSF products as
Transactional prices may vary; contact your supplier for actual prices.
If you no longer wish to receive email communications from GRANIX, please enter
your email address below and then click Submit. Your email address will be removed
from our mailing list.
*Required field. The email address you enter must be the same as the email address
to which news and information about GRANIX were sent.
Full Prescribing Information.
Reference: 1. This information is an estimate
derived from the use of information under license from the following IMS Health
Information Service: IMS National Sales Perspective, GRANIX® (tbo-filgrastim) Injection micrograms by non-federal
hospital channel February 2016. IMS expressly reserves all rights, including rights
of copying, distribution, and republication (micrograms calculated as eaches x strength).
©2016 Cephalon, Inc., a wholly-owned subsidiary of Teva Pharmaceutical Industries
Ltd. GRANIX is a registered trademark of Teva Pharmaceutical Industries Ltd.
All rights reserved. GRX-40884 June 2016